Murciano Revert J, Martínez-Lahuerta J J, Aleixandre Porcar L, Debón Belda M
Centro de Atención Primaria Pintor Stolz, Valencia.
Aten Primaria. 2001 Apr 15;27(6):417-21. doi: 10.1016/s0212-6567(01)78824-5.
To determine whether hypercholesterolaemia treatment with pravastatin causes modifications in plasma fibrinogen.
Descriptive, prospective pharmacological intervention study, with two transversal cuts, one at the start and one after 6 months pravastatin treatment.
Health area located in the suburbs of Valencia.
Hypercholesterolaemia cases diagnosed de novo and treated with pravastatin for 6 months. Sample size was calculated for paired data with an alpha error of 0.05 and a beta error of 20%. The fibrinogen difference thought relevant was set at 40 mg/dl. Variability was deduced from a mini-sample of 15 cases, obtaining a total of 57 patients. Sex, age, height, weight, BMI, count, formula, globular sedimentation rate (GSR), glucaemia, total, HDL and LDL cholesterol, and triglycerides were recorded.
Mean age was 55.9, height 161.9 cm and initial weight 73.9 kg (mean BMI 28.1 kg/m(2)). After six months pravastatin treatment (10/20 mg/day) we found no significant differences in glucaemia, GSR or leukocytes. There were differences in weight, that fell by 1.5 kg (0.6 kg/m(2)), systolic pressure (4.3 mmHg) and diastolic pressure (2.7 mmHg) on average. We found the following differences for lipids: 42.3 mg/dl (15.2%) drop in mean total cholesterol, 27 mg/dl (14.5%) in LDL cholesterol, and 36.2 mg/dl (21.9%) in triglycerides. We found a mean increase in HDL cholesterol of 4.4 mg/dl. There was a mean drop of 43.7 mg/dl (11.9%) in fibrinogen.
We found an 11.9% drop of plasma fibrinogen in patients with hypercholesterolaemia treated with pravastatin.
确定用普伐他汀治疗高胆固醇血症是否会引起血浆纤维蛋白原的改变。
描述性、前瞻性药理学干预研究，有两个横断面，一个在开始时，一个在普伐他汀治疗6个月后。
位于巴伦西亚郊区的健康区域。
初诊为高胆固醇血症并接受普伐他汀治疗6个月的患者。样本量是针对配对数据计算的，α错误率为0.05，β错误率为20%。认为相关的纤维蛋白原差异设定为40mg/dl。从15例的小样本中推断出变异性，共获得57例患者。记录了性别、年龄、身高、体重、BMI、计数、公式、球蛋白沉降率（GSR）、血糖、总胆固醇、高密度脂蛋白胆固醇（HDL）、低密度脂蛋白胆固醇（LDL）和甘油三酯。
平均年龄为55.9岁，身高161.9cm，初始体重73.9kg（平均BMI 28.1kg/m²）。普伐他汀治疗6个月（10/20mg/天）后，我们发现血糖、GSR或白细胞无显著差异。体重有差异，平均下降了1.5kg（0.6kg/m²），收缩压（4.3mmHg）和舒张压（2.7mmHg）。我们发现血脂有以下差异：平均总胆固醇下降42.3mg/dl（15.2%），低密度脂蛋白胆固醇下降27mg/dl（14.5%），甘油三酯下降36.2mg/dl（21.9%）。我们发现高密度脂蛋白胆固醇平均增加4.4mg/dl。纤维蛋白原平均下降43.7mg/dl（11.9%）。
我们发现用普伐他汀治疗的高胆固醇血症患者血浆纤维蛋白原有11.9%的下降。
